İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2010

Treatment of tumor lysis syndrome with the highest known uric acid level

Renal Failure

YÖKSİS OpenAlex Açık erişim · bronze SJR Q2 JCR Q4 Atıf 5 Yüzdelik 69.8% FWCI 0.45
Yıl
2010
ISSN
0886-022X
Tür
article

Veri kaynağı ayrımı

  • YÖKSİS YÖKSİS makale kaydı
  • OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)

Özet

İngilizce (OpenAlex)

Tumor lysis syndrome (TLS) is a disease with high mortality that develops in conditions characterized by rapid cell proliferation or after the cytotoxic treatment of malignant diseases. Extraction of intracellular ions and metabolites into the extracellular milieu following cell destruction causes hyperuricemia, hyperphosphatemia, hypocalcemia, hyperkalemia, and uremia. The prophylaxis and treatment of TLS includes intensive hydration, diuretics, alkalinization of the urine, allopurinol, and rasburicase. Close electrolyte monitoring of the patients is required. In the patients with acute renal failure (ARF), dialysis can be used either as the first treatment of choice or together with the above-mentioned prophylactic and therapeutic agents. Herein we report the effective treatment of a patient with anuric ARF by means of sequential hemodialysis sessions, in whom TLS developed after chemotherapy; the uric acid level was 71.3 mg/dL, which was considerably greater than the values reported in the literature.

Konular

  • Methemoglobinemia and Tumor Lysis Syndrome
  • Neonatal Health and Biochemistry
  • Porphyrin Metabolism and Disorders

Birincil konu Methemoglobinemia and Tumor Lysis Syndrome

Yazarlar

  1. GÜLSÜM ÖZKAN TEKİRDAĞ NAMIK KEMAL ÜNİVERSİTESİ
  2. ŞÜKRÜ ULUSOY
  3. MEHMET SÖNMEZ
  4. RUKİYE KÜBRA KAYNAR KARADENİZ TEKNİK ÜNİVERSİTESİ
  5. MUSTAFA KARAGÜLLE BİLECİK ŞEYH EDEBALİ ÜNİVERSİTESİ